Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment of HCV Genotype 4 with Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin
NCT04391985Phase 2Completed
- Sponsor
- Beni Suef University
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of sofosbuvir, ombitasvir, paritaprevir, ritonavir, ribavirin in hepatitis C (HCV), sponsored by Beni Suef University. Started Mar 2017; status: completed.
02
Drugs
sofosbuvirombitasvirparitaprevirritonavirribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04391985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391985.